PT-141 10mg nasal spray by Hudson Science. 166mcg per actuation, higher per spray dose format for melanocortin MC3R and MC4R receptor research. Lab tested, discreetly shipped across Canada. Intended for research purposes only.
Format10mg Nasal Spray
Concentration166mcg/Spray
Pack Size Selected: 5 Pack
Pay with Interac e-Transfer or Crypto
Ships from within Canada; No Customs
Discreet plain packaging; always
24h dispatch; Tracked Delivery
PT-141 (Bremelanotide) is a synthetic melanocortin peptide and direct metabolite of Melanotan II that achieved FDA approval under the brand name Vyleesi for hypoactive sexual desire disorder. Hudson Science’s nasal spray formulation delivers 10mg total PT-141 at 166mcg per metered spray actuation. A distinct concentration per spray from CSD’s existing Hudson Science PT-141 10mg nasal spray at 100mcg per spray, providing a higher per actuation dose that allows researchers to achieve target compound delivery in fewer spray actuations across the same total compound supply.
The 166mcg per spray concentration is a meaningful research variable within CSD’s PT-141 nasal spray range. At 100mcg per actuation the standard nasal spray delivers a more granular titration increment per spray, while the 166mcg per actuation format delivers a higher dose per actuation suited to protocols targeting concentration points that would require multiple actuations at the lower per spray dose. Both present identical total 10mg compound supply across their full actuation count. per spray concentration and total actuation count representing the differentiating variables between the two listings.
The nasal delivery route’s pharmacokinetic relevance for PT-141 remains consistent across both spray concentrations. PT-141’s primary research targets are MC3R and MC4R receptors concentrated in hypothalamic structures — the nasal route’s proximity to the olfactory epithelium and potential direct CNS access via the olfactory nerve pathway provides a meaningful pharmacokinetic advantage over peripheral subcutaneous injection for compounds targeting central melanocortin receptor populations. PT-141’s FDA approval under Vyleesi was achieved through subcutaneous injection, making intranasal delivery a distinct and separately studied administration route for comparative melanocortin bioavailability research.
Hudson Science formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD stocks PT-141 across two nasal spray concentrations: 100mcg and 166mcg per actuation, alongside the iLab Pharma 10mg lyophilized injectable vial, giving researchers per spray dose and delivery route flexibility from a single verified Canadian supplier. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Store at 2–8°C away from direct light. Do not freeze. Keep upright. Intended for research purposes only.
Commonly researched alongside Melanotan II in comparative melanocortin receptor selectivity and central nervous system signaling studies. Browse CSD’s full peptide range for complete sourcing.
